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Abstract
Chronic infections with the hepatitis B and C viruses have significant worldwide 
health and economic impacts. Previous treatments for hepatitis C such as 
interferon and ribavirin therapy were ineffective and poorly tolerated by patients. 
The introduction of directly acting curative antiviral therapy for hepatitis C and 
the wider use of nucleos(t)ide analogues for suppression of chronic Hepatitis B 
infection have resulted in many positive developments. Decreasing the prevalence 
of hepatitis B and C have concurrently reduced transmission rates and hence, the 
number of new infections. Antiviral treatments have decreased the rates of liver 
decompensation and as a result, lowered hospitalisation and mortality rates for 
both chronic hepatitis B and C infection. The quality of life of chronically infected 
patients has also been improved significantly by modern treatment. Antiviral 
therapy has stopped the progression of liver disease to cirrhosis in certain patient 
cohorts and prevented ongoing hepatocellular damage in patients with existing 
cirrhosis. Longer term benefits of antiviral therapy include a reduced risk of 
developing hepatocellular carcinoma and decreased number of patients requiring 
liver transplantation. This review article assesses the literature and summarises 
the impact of modern antiviral therapy of chronic hepatitis B and C on clinical 
outcomes from liver disease.
Key Words: Hepatitis B; Hepatitis C; Nucleotide analogues; Directly acting antiviral 
therapy; Clinical outcomes; Liver disease
©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
Khoo T et al. Modern antiviral therapy and liver disease
WJG https://www.wjgnet.com 4832 August 7, 2021 Volume 27 Issue 29
Australia
Peer-review report’s scientific 
quality classification
Grade A (Excellent): 0 
Grade B (Very good): B 
Grade C (Good): 0 
Grade D (Fair): 0 
Grade E (Poor): 0
Received: January 29, 2021 
Peer-review started: January 29, 
2021 
First decision: May 2, 2021 
Revised: May 14, 2021 
Accepted: July 21, 2021 
Article in press: July 21, 2021 
Published online: August 7, 2021
P-Reviewer: Ferraioli G 
S-Editor: Ma YJ 
L-Editor: A 
P-Editor: Liu JH
Core Tip: Hepatitis B and C infection contribute significantly to the global burden of 
liver disease. With the introduction of modern antiviral therapy, there is now an 
effective curative treatment for hepatitis C and potent suppressive antiviral therapy for 
hepatitis B. Antiviral therapy has had a positive impact on liver disease by reducing 
hospitalisation rates and hence, cost to global health systems. Rates of decompensation, 
hepatocellular carcinoma and need for transplantation have all been lowered. This 
review article assesses the literature and summarises the impact of modern antiviral 
therapy of chronic hepatitis B and C on clinical outcomes from liver disease.
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Chronic viral hepatitis B and C infections remain a significant burden on global health. 
Modern directly acting antivirals (DAAs) have changed the landscape of hepatitis C 
virus (HCV) treatment with their high rates of sustained virological response and 
superior tolerability. HCV has a significant global impact with the World Health 
Organisation estimating that 71 million people worldwide are chronically infected[1]. 
Between 15%-30% of patients with chronic HCV infection will develop cirrhosis and its 
related complications within 20 years. On the other hand, despite the development 
and wide availability of the hepatitis B vaccine, WHO estimated that the global 
incidence of chronic hepatitis B virus (HBV) infection was 257 million people in 2015
[2].
Both of these chronic diseases result in substantial economic burden. The mean 
annual all-cause medical cost for healthcare in an American cohort with HCV was 
$43891 as compared to $17989 in patients without HCV[3]. A retrospective study 
which conducted an analysis on the United States Veteran population with chronic 
HBV, calculated the total cost per patient per year to be $39240 for those treated with 
nucleoside analogues[4]. Treatment of HCV, particularly in the early stages of fibrosis, 
significantly mitigates the economic burden from HCV and its resultant hepatic 
complications[3]. The cost of treatment of HBV has decreased significantly over the 
decades as Entecavir and Tenofovir disproxil fumurate are now both off-patent. On 
the international market, the median price of WHO-prequalified generic Tenofovir has 
been reduced from US$208 per year to US$32 per year in 2016[2]. Cost of HCV 
treatment with DAAs is significant, ranging from $40000 to $90000 depending on the 
drug and treatment duration. Thankfully, many countries such as Australia and 
Canada have heavily subsidised treatment, allowing the widespread use of DAAs.
The advent of modern DAA therapies has revolutionised the treatment of HCV. 
More patients are willing to start treatment with the promise of high cure rates, shorter 
durations of treatment and limited adverse effects. Early access to effective curative 
treatment will have significant long-term impact on the outcomes of HCV related liver 
disease. Advances in HCV therapy have led to a commitment by the member states of 
WHO to try to eliminate viral hepatitis by 2030. For HBV therapy, nucleos(t)ide 
analogues (NA) are potent antiviral agents which are becoming more widely available 
in low to middle economic countries. NAs suppress viral replication and therefore 
result in improved long-term clinical outcomes in chronic liver disease by reducing the 
progression of liver injury to advanced fibrosis, cirrhosis, liver failure and hepato-
cellular carcinoma (HCC). As a direct consequence, the requirements for liver 
transplantation are also reduced[5,6].
The aim of this review article is to summarise the current literature regarding 
modern antiviral treatment of chronic HBV and HCV infection and the effects of 
therapy on clinical outcomes of chronic liver disease.
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EFFECTS OF CHRONIC HEPATITIS B TREATMENT ON CLINICAL  
OUTCOMES
Prevalence
Globally, chronic HBV is one of the most common infectious diseases[7]. In 2015, the 
World Health Organisation (WHO) estimated that 257 million people, equivalent to 
approximately 3.5% of the world’s population, were living with chronic HBV[7]. In 
addition, 2.7 million people were coinfected with HBV and HIV[7]. Chronic HBV is 
associated with development of complications including cirrhosis, liver failure and 
hepatocellular carcinoma. HBV is a leading cause of liver cancer worldwide[8] and up 
to one in four people with chronic HBV will die from liver cancer or liver failure if 
their HBV is not monitored or treated appropriately[7]. The prevalence of HBV varies 
widely depending on country and is predominantly determined by age of exposure; 
approximately 90% of infected infants progress to develop chronic HBV, as opposed to 
a rate of 5% following exposure of immunocompetent adults to HBV[9]. In 2015, 65% 
of all infected persons with HBV were located in African and Western Pacific regions
[7].
Chronic HBV infection is preventable using a readily accessible vaccine. In 2017 
there were 4762 confirmed HBV cases reported in the United Kingdom and of these, 
324 were acute cases of HBV[10]. The prevalence of HBV has been reduced through 
the incorporation of routine vaccination in the immunisation schedule in Australia and 
United Kingdom. In 2017, there was a 73% self-reported uptake of at least one dose of 
the HBV vaccine in England[11]. In Australia, there were an estimated 226566 people 
(0.9% of the population) living with chronic HBV[12]. Additionally, it is estimated that 
of those living with chronic HBV, only 68% have been diagnosed[12]. In 2020, only 
22% people with chronic HBV were engaged with regular care and receiving regular 
monitoring or antiviral therapy[12]. Furthermore, only 9.3% were receiving antiviral 
therapy[13]. The national target in Australia is to have 50% of chronic HBV patients 
engaged with care and 20% receiving antiviral therapy by 2022[12].
Decompensation and mortality
Currently, chronic infection with HBV remains incurable. The goals of modern 
antiviral therapy for chronic HBV are to (1) improve survival and quality of life by 
preventing disease progression to cirrhosis, decompensation and HCC; (2) induce 
virological seroconversion of e-antigen and surface antigen; (3) induce long-term 
suppression of HBV DNA levels; and (4) induce normalisation of serum alanine 
aminotransferase (ALT) levels which reflect a biochemical response to therapy[14].
Chronic HBV infection can progress to advanced hepatic fibrosis and eventually, 
cirrhosis. Hepatic decompensation can occur in the context of cirrhosis or acute flare as 
a result of HBV reactivation. Decompensation presents clinically with the development 
of ascites, jaundice, encephalopathy or variceal bleeding. In HBV infection, hepatic 
decompensation occurs with a high HBV-DNA viral load and is more common in 
patients who are e-Ag positive[15].
Hui et al[16] conducted a study of 96 chronic HBV patients over three years and 
reported 29% of patients developed decompensation. The most common clinical 
manifestation of decompensation was ascites (70%) followed by variceal bleeding 
(34%), jaundice (26%) and hepatic encephalopathy (5%). Almost a third of subjects had 
more than one feature of decompensation. Das et al[17] performed a retrospective 
cohort study involving 253 HBV-related decompensated cirrhotic patients. They 
reported a mean 5-year survival rate of 19%; the commonest causes of death included 
hepatorenal syndrome (32%), HCC (28%), variceal bleeding (23%), liver failure (9%) 
and hepatic encephalopathy (9%).
Acute-on-chronic liver failure is associated with a high mortality rate and occurs in 
patients with chronic HBV who have experienced an acute liver decompensation event 
which results in jaundice, ascites, coagulopathy and/or encephalopathy[15]. Acute 
liver insults may result from recrudescence of HBV replication, viral superinfection 
(with hepatitis D, HCV, or hepatitis E virus), acute variceal bleeding, infection and/or 
alcoholic hepatitis[15]. Studies assessing acute-on-chronic liver failure in patients with 
chronic HBV infection report that antiviral therapy (including Entecavir and 
Tenofovir) reduces all-cause mortality[15,18,19].
Antiviral therapy suppresses viral replication and reduces the likelihood of loss of 
hepatic function. The literature shows that antiviral therapy reduces the probability of 
decompensation and progression of liver cirrhosis[15] (Figure 1). The use of antiviral 
therapy in HBV-related liver decompensation results in improvement of liver function, 
as illustrated by improved MELD scores and patients being delisted for liver 
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Figure 1 Outcomes of hepatitis B after introduction of antiviral therapy. HCC: Hepatocellular carcinoma; HBV: Hepatitis B virus.
Figure 2 Outcomes of hepatitis C after introduction of antiviral therapy. HCC: Hepatocellular carcinoma; MELD: Model of End stage Liver Disease; HCV: Hepatitis C virus.
transplantation[15]. Therefore, guidelines recommend commencement of antiviral 
therapy in all cirrhotic patients with HBV, irrespective of viral load level. A Korean 
study by Kim et al[20] demonstrated a 15% probability of developing hepatic decom-
pensation 5-years after commencement of antiviral therapy which was less compared 
to those who remained untreated and had a 45% probability of decompensation after 5 
years. Overall, treatment with antivirals results in significantly improved prognosis in 
HBV-related cirrhosis as evidenced by 5 year survival rates of 81% in those treated 
with NAs compared to 56% in the untreated individuals[20].
Nucleos(t)ide analogues such as Entecavir and Tenofovir disoproxil fumurate (TDF) 
are considered first line agents due to their excellent safety profile, high efficacy and 
minimal to no risk of resistance developing in treatment-naïve patients[15]. Entecavir 
induces undetectable viral load in up to 89% of patients with decompensated liver 
disease after 12 mo[21,22]. Additionally, commencement of antiviral therapy is 
associated with improvement in prognosis, with a substantial reduction in Model of 
End stage Liver Disease (MELD) and Child-Pugh (CP) scores after twelve months of 
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therapy[15]. Several studies have reported a mean improvement of both MELD and 
CP scores by up to 2 points (compared to baseline) at twelve months in patients who 
respond to treatment with Entecavir or TDF[21,23-26].
Pegylated-interferon alpha could be considered as an initial treatment option for 
patients with compensated cirrhosis, with a treatment duration of 48 wk. It is contrain-
dicated in patients with hepatic decompensation. Observational studies which 
followed up patients for a mean of 84 months and compared treatment with 
pegylated-interferon alpha vs no treatment reported a significant decrease in the risk 
of HCC, with a cumulative incidence rate of 14% at 5 years in those treated vs 23% in 
untreated patients. There was no difference in all-cause mortality or decompensated 
liver disease[17,20,27-29].
Several studies have shown that antiviral therapy improves mortality in liver 
cirrhosis. Suppression of viral replication prevents progression of liver disease and 
therefore reduces the risk of liver decompensation and HCC, resulting in improved 
overall survival. The 5-year survival rate in untreated patients with HBV with 
compensated cirrhosis is 80%-85% vs 14%-35% in decompensated cirrhosis[15]. 
Additionally, a Korean cohort study of 204 patients demonstrated the positive 
prognostic effect of antiviral therapy in cirrhotic patients with HBV[20]. This study 
reported the 5-year survival rate in untreated cirrhotic patients was 56%; the survival 
breakdown based on CP score was 74% for CP-A, 34% for CP-B and 10% for CP-C[20]. 
For those who were treated with antiviral therapy, the overall 5-year survival rates 
were 81%; 91% for CP-A, 63% for CP-B and 62% for CP-C[20].
A large study by Jang et al[26] which followed 707 patients with HBV-related 
decompensation for seven years illustrated the long-term benefits of viral suppression 
in decompensated cirrhotic patients and a trend to benefit in regard to transplant-free 
survival with antiviral therapy. This study reported a 5-year transplant-free survival of 
nearly 60% with antiviral therapy compared with 46% in the untreated group. Usually, 
patients with chronic HBV-related decompensated cirrhosis who are listed for 
transplantation have a much lower 5-year survival compared with those who undergo 
transplantation with fulminant HBV infection[26]. In addition, up to 60% of those 
patients listed for transplantation were able to either delay or negate the need for liver 
transplantation[26]. However, of the patients with severe hepatic dysfunction in this 
study, 13% of patients died within first six months of initiating antiviral treatment[26]. 
Hence, patients with severe decompensation should be considered for liver tran-
splantation because it may take several months of antiviral therapy for liver function 
to recover.
HCC 
Recent studies have reported that the incidence of annual HCC in patients with 
chronic HBV ranges from 0.9%–1.4% in non-cirrhotic patients and up to 5.4% in those 
with cirrhosis[30]. The majority of the published literature demonstrates that antiviral 
therapy with nucleos(t)ide analogues (NAs) reduces the risk of HCC in patients with 
chronic HBV, after adjusting for known background risk factors including older age, 
male gender, cirrhosis, family history, HBeAg positive status, elevated HBV DNA and 
serum ALT levels[13,31,32]. Asian studies that compared data with or without NA 
treatment reported significant treatment-related reductions in risk of HCC risk by up 
to 30% in cirrhotic patients and 80% in non-cirrhotic patients[30].
Hosaka et al[29] compared 472 Entecavir-treated patients with 1143 untreated 
patients and found that the incidence rate of HCC at 5 years was 3.7% in the Entecavir 
group and 13.7% in the control group, after elimination of baseline differences by 
propensity score matching. Additionally, after adjustment for a number of known 
HCC risk factors, Entecavir treatment was independently associated with reduced 
HCC risk[29]. A European multicentre study reported that the HCC risk began to 
decrease after 5 years of antiviral therapy[33]. The reduction in HCC incidence with 
treatment was further supported by a Taiwanese nationwide study which assessed 
propensity score-matched patients on antiviral therapy; those receiving NA therapy 
had a significantly lower 7 year HCC incidence of 7% compared to 23% in the 
untreated cohort[13]. The benefit of antiviral treatment was observed in both non-
cirrhotic and cirrhotic patients[13].
A large study conducted by Lee et al[5] which consisted of a post-hoc analysis of 
two prospective cohorts from Hong Kong and Korea (n = 818 patients), reported the 
risk of HCC did not decrease after 5 years of antiviral therapy. This study finding 
suggests that cirrhotic patients may require longer therapy before a decline in HCC 
risk eventuates[5]. The higher rates of HCC may also reflect improved mortality rates 
related to current clinical practice, which translates to more time for HCC to develop
[34].
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The mechanisms by which antiviral therapy decrease HCC risk may include 
reductions in the hepatic inflammation and nuclear signaling pathways that lead to 
neoplastic transformation on a cellular level[35,36]. NAs also reverse fibrosis and the 
wound-healing response known to be associated with the pathogenesis of HCC[37]. 
Antiviral therapy may reduce the expression of hepatitis B x-protein to levels that are 
insufficient for HCC development, or act at a genomic level by preventing integration 
of HBV DNA into host chromosomes and thus affect its malignant potential[38].
Thus, HCC risk is not completely eliminated with modern antiviral therapy, and 
there remains a risk of developing HCC even in the context of negative hepatitis B e 
antigen (HBeAg) and/or negative hepatitis B surface antigen (HBsAg) status[39-42]. 
Seroconversion of HBsAg is associated with better clinical outcomes and lower rates of 
HCC incidence[32]. Even so, several studies have illustrated that the risk of HCC 
remains elevated in treated HBeAg-negative patients for at least 5 years after initiation 
of NA treatment. Therefore, HCC surveillance should be continued long term, even 
after seroconversion of HBsAg[31,40,43].
The association between virological suppression and HCC development remains 
controversial due to conflicting results. In Asian studies, virological suppression is 
associated with lower rates of HCC – especially in cirrhotics[30,32]. On the other hand, 
European studies have not consistently reported this association. This difference may 
be related to variation in patient characteristics such as genotype distribution[6].
A Greek cohort with 321 HBeAg-negative chronic HBV patients treated with 
Entecavir, reported an HCC incidence of 1.2% at a median follow-up of 1.5 years[40]. 
The 5-year cumulative HCC incidence rate in Entecavir-treated patients was 9% in 
cirrhotic patients and less than 1% in non-cirrhotic patients[40]. This result was similar 
to two other Asian studies[29,44]. Old age was identified to be an independent risk 
factor associated with increased risk of HCC[40]. A Korean retrospective analysis of 
829 patients who had achieved seroconversion of HBsAg and followed up over 3464 
patient-years found that the annual rate of HCC was 0.6%; the estimated annual 
incidence of HCC was 3% in cirrhotic patients and 0.3% in non-cirrhotic patients[39]. 
Independent risk factors associated with the development of HCC included liver 
cirrhosis, male gender and age[3] 50 years at time of HBsAg seroconversion[39]. 
Therefore, HCC surveillance should be recommended to continue in patients who 
have undergone HBsAg seroconversion if they are cirrhotic or over the age of 50 years, 
regardless of cirrhotic status[39].
In patients who have undergone resection of HCC, an elevated viral load and 
absence of antiviral therapy are independent risk factors for recurrence of HCC[45]. 
Choi et al[34] conducted a historical cohort study of 1695 patients treated with 
Entecavir (n = 813) or TDF (n = 882) after curative intent hepatectomy for early-stage 
HCC (BCLC Stage 0/A) between 2010 and 2018. During a median follow-up duration 
of 38 months with continuous antiviral therapy, 33% of patients developed HCC 
recurrence. A comparison between Entecavir and TDF therapy revealed that TDF was 
associated with a significantly higher recurrence-free survival, higher overall survival 
rates and lower rates of HCC recurrence. The 3-year recurrence free survival rates 
were 73% and 64% in the TDF and Entecavir groups, respectively. TDF was also 
significantly associated with a lower risk of both early (i.e., within 2-years of resection) 
(adjusted hazard ratio 0.79, 95%CI, 0.64-0.97, P = 0.03) and late HCC recurrence 
(adjusted hazard ratio, 0.68; 95%CI, 0.47-0.97; P = 0.03) compared to Entecavir. Whilst 
the results of this study imply better clinical outcomes associated with TDF in regard 
to rates of recurrence of HCC, this was an observational study which may be subject to 
bias and confounding. Additionally, other limitations of the study include missing 
data, heterogeneity in duration of antiviral therapy treatment (i.e., before or after 
surgery), and TDF being approved as standard-of-care therapy in Korea in December 
2020 which falls within the study period.
Liver transplantation
NAs have been associated with reduced rates of liver transplantation for patients with 
chronic hepatitis B. A retrospective study included 5374 patients with chronic HBV, 
2000 patients were treated with NA (Entecavir) and 3374 patients were treated with 
Lamivudine in a tertiary centre in South Korea[46]. The study demonstrated that 
Entecavir was associated with a significantly lower risk of death or transplantation 
(hazard ratio 0.49, 95%CI 0.38-0.64)[46]. A further analysis of 860 paired cirrhotic 
patients replicated the finding (hazard ratio 0.42, 95%CI 0.31– 0.57)[46].
Recurrence of HBV post-liver transplantation occurs when circulating HBV virions 
from extrahepatic reservoirs engraft the new liver. HBV re-infection has been 
associated with early acute cellular rejection within the first year of liver trans-
plantation[47]. Risk factors associated with HBV recurrence include high level of 
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viraemia at time of transplantation, HBeAg-positive status, or history of drug re-
sistance to oral HBV antiviral therapy[47,48]. Post-transplant immunosuppression can 
also induce viral replication and subsequent HBV infection in patients who have 
received donor liver graft with hepatitis B core antibody positivity[49]. Administration 
of hepatitis B immunoglobulin (HBIG) to transplant recipients has been associated 
with lower HBV recurrence and improved survival of 80%, compared to 80% HBV 
recurrence and 50% survival if no HBIG was given[47,48]. The addition of NA therapy 
to HBIG in liver transplant recipients has resulted in a further reduction in HBV 
recurrence and improved prognosis[47]. A study conducted by Cholongitas et al[50] 
which had a median follow up period of 30 mo, reported HBV recurrence was much 
lower in patients who received HBIG plus NA (Entecavir/Tenofovir) – 1%, compared 
to those who received HBIG plus Lamivudine – 6% (P = 0.0004).
Extrahepatic manifestations
Extrahepatic manifestations may be observed with acute or chronic HBV infection. It is 
postulated that circulating immune complexes and viral antigens activate the 
complement cascade resulting in organ injury, most commonly to the kidneys, vessel 
wall, skin and joints[51]. A multicentre retrospective cross-sectional study of HBV 
patients and found that 16% exhibited clinical extrahepatic manifestations - sensory-
motor deficiency, sicca syndrome, myalgia, glomerulonephritis and arthralgia arthritis 
[52]. Other associations reported in the literature include a serum sickness-like 
syndrome, polyarteritis nodosa, cryoglobulinaemia, lichen planus, Gianotti-Crosti 
syndrome and Guillain-Barre syndrome. Awareness and recognition of these clinical 
manifestations are important to facilitate early diagnosis, monitoring and treatment of 
HBV infection and the associated organ injury.
Infection with HBV is associated with a variety of renal diseases including mem-
branous nephropathy, membranoproliferative glomerulonephritis and rarely IgA 
nephropathy. A prospective French study by Mallet et al[53] monitored the renal 
function of patients with compensated chronic HBV following treatment with NAs. 
Treatment with TDF or Entecavir, especially in patients with an initial HBV DNA titre 
of 100 000IU/mL or greater, resulted in an increased estimated Glomerular filtration 
rate (eGFR) throughout the follow up period (median of 2.7 years)[53]. Similarly, a 
recent meta-analysis by Fu et al[54] assessed the efficacy and safety of NA mono-
therapy for HBV-related glomerulonephritis in 7 trials involving 182 participants. 
They found that antiviral therapy induced remission of proteinuria and increased 
HBeAg clearance.
Polyarteritis nodosa (PAN) is a multisystem necrotizing vasculitis typically affecting 
muscular medium-sized and small arteries. Hepatitis B has been observed in 17%-35% 
of patients diagnosed with PAN, although the frequency is likely decreasing due to 
HBV vaccination[55]. The American College of Rheumatology (ACR) has established 
ten criteria for the classification of PAN in patients with a vasculitis and recognises the 
evidence of HBV infection as one of the diagnostic criteria[56]. Other systemic features 
of PAN may include cutaneous livedo reticularis, testicular pain, mononeuropathy or 
polyneuropathy, renal artery aneurysm and unexpected weight loss. In patients in 
whom PAN is associated with HBV (HBV-PAN), the major focus of therapy is the use 
of antiviral agents for the treatment of the underlying viral disorder. Immunosup-
pressive therapy in the form of glucocorticoids may also be used in the short term for 
control of the systemic inflammation[55]. In several studies, clinical remission of PAN 
was observed in patients who were treated with antiviral agents and in very few 
patients who instead received only immunosuppressive treatment[55,57].
Mixed cryoglobulinaemia (types II and III) is caused by immunocomplexes 
composed of polyclonal IgG in association with either monoclonal or polyclonal IgM. 
These immunoglobulins precipitate with cold temperature, resulting in purpura, renal 
disease, arthralgia or arthritis. Cryoglobulinaemic vasculitis can develop in 1-4% of 
HBV patients. Treatment with NAs has been found to provide significant clinical 
response, preventing extrahepatic organ complications[58].
EFFECTS OF CHRONIC HEPATITIS C TREATMENT ON CLINICAL  
OUTCOMES
Prevalence 
The WHO estimates that there are up to 71 million people worldwide who are 
chronically infected with HCV[1]. In Australia, mandatory reporting of HCV diagnosis 
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has been required since the 1990s. This allows for more accurate assessment of HCV 
numbers. As of 2017, it was estimated that up to 182,144 people in Australia had HCV. 
The incidence of new HCV infections has steadily declined since 2000. Government 
subsidised DAA treatment was made generally available in 2016. At the end of 2018, 
an estimated 130089 Australians had HCV, a decrease of approximately 50000 patients 
with the use of antiviral therapy (Figure 2).
In the United Kingdom, the prevalence is estimated to have decreased in recent 
years by one-third due to DAA treatment. Approximately 118000 people had HCV in 
2019 as compared to 174000 in 2015[59]. It is expected that the prevalence will continue 
to steadily decrease with a corresponding increase in the number of patients who have 
been successfully treated.
Decompensation and mortality 
It is well recognised that chronic HCV places considerable financial burden on the 
healthcare system, primarily related to presentations with decompensated liver 
disease. These individuals have prolonged stays in hospital and frequent re-
admissions. A United Kingdom study demonstrated that 21.1 d was the mean length 
of stay in decompensated HCV patients without HCC. This translates to a mean cost of 
9120 pounds per year. Within Europe, annual hospitalisation costs are estimated at 
8000-20000 euros for decompensated patients in France and up to 28000 euros in the 
Netherlands. The inpatient hospital burden appears to be greatest within the first year 
after the first decompensation event[60]. With the aging population, there are 
increasing numbers of patients presenting to Emergency Departments with HCV-
related issues which result in hospitalisation[61]. In the Scottish population, between 
1996 and 2013, the total number of HCV-related inpatient admissions with 
decompensation increased 16-fold[60].
In the United Kingdom-based Extended Access Program cohort, achieving a 
sustained viral response (SVR) in HCV cirrhotics was associated with a reduction in 
decompensation rates of 18% within the first 6 mo[62]. Lower decompensation rates 
result in decreased hospitalisation rates, reduced length of stay and most importantly, 
mortality reduction[63]. In the Veterans Affairs cohort, achieving SVR in patients with 
advanced liver disease (pre-treatment FIB-4 scores of > 3.25) resulted in a 74% 
reduction in mortality risk, after adjusting for baseline variables[64].
A rise in the hepatic venous pressure gradient (HVPG) is the main driver behind 
cirrhosis-related complications such as variceal bleeding and ascites. HCV eradication 
is associated with a reduction in HVPG which translates to decreased complications. 
This was demonstrated in a prospective study by Mandorfer et al[65] who measured 
HVPG pre- and post-treatment of HCV. In patients with subclinical portal hyper-
tension (HVPG 6-9 mmHg), portal hypertension resolved in 63% of patients. In the 
group of patients with HVPG 10-15 mmHg, portal hypertension resolved in 43% of the 
cohort. The highest risk group with HVPG > 16 mmHg showed a reduction in HVPG 
in 35% of patients but portal hypertension did not resolve in any of the patients[65]. 
This indicates the importance of treating HCV early to achieve SVR and reversibility of 
portal hypertension prior to development of end-stage irreversible portal hypertension 
and its related complications.
Quality of life
Chronic HCV infection has clearly defined effects on hepatic fibrosis, cirrhosis and 
subsequently, increased risk of HCC. There have been many studies looking into the 
clinical effects of hepatitis C-related liver disease. Patient related outcomes (PROs) or 
impact on quality of life are equally important measures but harder to quantify. 
Previous studies have demonstrated that health-related quality of life (HRQOL) is 
impacted by HCV and HCV causes a more severe reduction in HRQOL than certain 
chronic diseases such as diabetes[66,67].
Cacoub et al[68] investigated the impact of HCV treatment on patient-related 
outcomes in a large study. Data were derived from 11 multicentre phase 3 clinical 
trials across a range of countries. These included trials based on interferon therapy, 
ribavirin-based and DAA therapies. PROs were measured using a combination of four 
different validated questionnaires to encompass different domains including physical, 
emotional and social impact as well as work productivity, fatigue and functional well-
being. Patients were asked to fill in the questionnaires at baseline, during treatment 
and post-treatment while being blinded to their HCV RNA levels.
This study demonstrated that modern antiviral therapy was associated with 
improvement in PROs as early as four weeks after initiation of treatment[68]. By week 
4, average PRO scores had improved by 6%, with the greatest improvements in the 
domain of emotional wellbeing and worry. This pattern continued throughout 
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treatment course (increased by 8%) and was sustained up to SVR-24 (increased by 
10%), becoming more pronounced with time. PROs were significantly better in the 
non-interferon, non-ribavirin group[68]. This provides additional support for the 
superiority of modern DAAs over older treatment regimes.
A systematic review by Younossi et al[69] also demonstrated that HCV infection 
negatively impacted patients’ HRQOL. In particular, scores were lower in the mental 
health domains as compared to physical health. The prevalence of depression in HCV 
patients was estimated to be 24% compared to 17% in the non-HCV control group. 
Based on this data, the risk of developing depression in patients with HCV is substan-
tially increased (RR = 2.30)[69]. In addition to the physical benefits derived by HCV 
clearance, the significant mental health improvements are also an important reason to 
treat HCV patients as early as possible.
HCC
HCC is the second leading cause of cancer-related death worldwide. Early on in the 
post-DAA treatment era, there was initial concern about an unexpected increase in the 
incidence of HCC after achieving viral clearance. These results were later disputed by 
other studies which had longer follow-up periods and larger cohorts with control 
groups. A cohort study by Kanwal et al[70] demonstrated that SVR was associated 
with a significantly lower risk of HCC as compared to patients who remained infected 
(0.90 vs 3.45 HCC per 100-person years; adjusted HR = 0.28). Two large cohort studies 
by Ioannou et al[71] and Singer et al[72] also showed a significantly reduced risk of 
HCC following SVR with adjusted HR = 0.84 and 0.29, respectively. Cheung et al[62] 
carried out a prospective study involving 406 patients with decompensated cirrhosis 
and demonstrated that the incidence of HCC was 4% within the first 6 months of DAA 
treatment. This was equivalent to the matched control group with untreated patients. 
The evidence now overwhelmingly favours the absence of any increased risk of HCC 
following SVR[73,74].
Post-treatment studies from the interferon era have shown that regression of fibrosis 
is a gradual process that can take years. As fibrosis assessment is mostly performed 
using non-invasive markers now, there is limited data assessing fibrosis regression 
post SVR with DAAs using the gold standard of liver biopsy. One small study showed 
that cirrhosis resolved in 7 out of 14 patients following DAA treatment[75]. A large 
retrospective Brazilian study of 400 patients reported that liver stiffness measurement 
(measured with Fibroscan) decreased significantly post-SVR (13.6 kPa vs 10.2 kPa, P < 
0.001) with 42% of the treated cohort experiencing a reduction of LSM by at least 30%
[76]. Thus, early viral clearance offers advantages of prevention and regression of 
hepatic fibrosis.
Although treatment with DAAs does not confer additional risk of HCC develo-
pment, it is still important to note that patients remain at risk of HCC even following 
SVR. Multivariate analyses from several studies have identified risk factors for HCC 
occurrence post DAA treatment. These include advanced liver fibrosis (F3 or F4), older 
age and male sex[77,78]. Therefore, it is imperative that patients with these risk factors 
should continue to undergo HCC surveillance even after successfully achieving viral 
clearance.
Liver transplantation 
HCV is one of the leading reasons for liver transplantation in the Western world. 
Twenty-four percent of liver transplants performed in Europe between 1999 and 2009 
were HCV-related[79]. The recurrence of HCV post-transplant was also an issue 
leading to accelerated graft dysfunction and eventual failure. DAA treatment can 
reduce the need for transplantation by reducing decompensation rates. A pooled 
analysis of 800 decompensated cirrhotic patients demonstrated that up to 60% of 
patients had an improvement of their MELD score after treatment[62]. In the United 
Kingdom, the introduction of treatment with DAAs has resulted in a decreased 
number of HCV-related cirrhosis patients being listed for transplant. The rate in 2013 
of new registrations with HCV-related cirrhosis was 10% and this reduced to 5% in 
2016 (P < 0.001) In this cohort, the median UKELD for HCV remained stable at 55 in 
the pre and post-DAA era[62,80,81]. There has been concern that treatment of HCV 
patients on the transplant waitlist will decrease their MELD score, reducing their 
chances of receiving a transplant. Despite the reduction in their MELD score, some of 
these patients still require a transplant as they are experiencing symptoms of 
decompensation. Ironically, the lower MELD score makes it less likely for them to 
receive a transplant, thus leaving this group of patients in “purgatory”. This data 
indicates that the threshold which physicians were using for listing patients had not 
changed over time and that the concept of entering “MELD purgatory” was not 
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occurring in the United Kingdom[81].
Other centres in Europe have reported an improvement in liver function of HCV 
patients on the transplant waitlist following DAA treatment to the point where up to 1 
in 4 patients can be removed from the waitlist or delisted. This decline in listing 
numbers is similar to that noted a decade ago after the introduction of antiviral 
therapy for hepatitis B. In an era where there is a chronic shortage of donor organs and 
an increasing need, early treatment with DAAs is beneficial in reducing the number of 
patients needing to progress to transplant[82,83].
HCV recurrence in the graft was a common problem post-transplant in patients 
with HCV. This contributed to accelerated fibrosis progression due to an immune 
incompetent state, resulting in graft dysfunction and eventual failure. With the 
introduction of DAAs, treatment of HCV recurrence in the post-transplant setting now 
prevents graft loss and the need for re-transplantation in this cohort[82,83].
Extrahepatic manifestations 
HCV infection has an impact not only on the liver, but also systemically. A meta-
analysis of 22 studies demonstrated that HCV infection increases the risk of 
cardiovascular mortality, with a two-fold higher risk of subclinical carotid plaques 
amongst HCV patients. HCV patients also have a higher risk of peripheral artery 
disease, cardiovascular events and cardiovascular mortality[84]. These changes are 
theorized to be due to systemic inflammation and release of inflammatory cytokines 
within the body caused by the virus. Based on this theory, treatment of HCV should 
result in a reduction in risk of extrahepatic manifestations.
A prospective Italian study by Nevola et al[85] evaluated HCV patients before and 
24 wk after treatment with DAAs. After achieving SVR, patients demonstrated an 
improvement in fasting blood glucose levels and reduced insulin resistance, regardless 
of the fibrosis state. In patients with impaired fasting glucose pre-treatment, 32% had 
normal blood glucose levels following SVR. Forty-five percent of diabetic patients 
experienced an improvement in glycaemic control, with some patients managing to 
reduce or cease their diabetic medications[85]. This indicates that HCV clearance is 
associated with a significant change in glucose metabolism, independent of baseline 
BMI. This has also been confirmed by other studies[86-90].
Changes in lipid profiles also occur following SVR, commonly manifest with an 
increase in LDL levels. The effect on HDL and triglycerides is less consistent across 
studies[91-95]. Lipid disturbances require closer monitoring in patients who have 
achieved viral clearance. Although lipid profiles may deteriorate following SVR, renal 
function improves. Patients in the Nevola cohort experienced an improvement in 
eGFR by 10% compared to baseline, regardless of the fibrosis status[85].
Depression is co-morbid with HCV infection in up to one-third of cases. Patients are 
often marginalized and experience psychosocial stigma due to their positive HCV 
status. From a physiological standpoint, it is thought that the systemic inflammation 
caused by the virus and the invasion of HCV into the nervous system results in 
disruptions of neurotransmission pathways. Moez et al[96] used the Beck Depression 
inventory scale to prospectively assess change post HCV treatment in their cohort of 
Egyptian patients and found a significant decrease in scores 1 month and 3 months 
post-SVR which correlated with an improvement in mood symptoms.
CONCLUSION
The use of NAs in HBV and DAAs in HCV has resulted in substantial benefits to 
patients who suffer with these chronic diseases. The therapeutic benefits gained from 
treatment encompass not only manifest as improvements in physical and mental 
health but also quality of life and economic health burden. It is hoped that there will 
be effective curative treatment for HBV in the coming years. Although there has been a 
decrease in the incidence of chronic HCV with the introduction of DAAs, there is still 
much work to be done before achieving the WHO’s target of HCV eradication by 2030. 
Reaching this target will require further screening, especially in at-risk groups, and 
more widespread subsidised use of DAAs worldwide.
REFERENCES
World Health Organization.   Hepatitis C 2020. Available from: https://www.who.int/health-
topics/hepatitis#tab=tab_1
1     
Khoo T et al. Modern antiviral therapy and liver disease
WJG https://www.wjgnet.com 4841 August 7, 2021 Volume 27 Issue 29
World Health Organization.   Hepatitis B (Fact sheet no. 204). 2008. Available from: 
https://www.who.int/news-room/fact-sheets/detail/hepatitis-b
2     
Reau N, Vekeman F, Wu E, Bao Y, Gonzalez YS. Prevalence and economic burden of extrahepatic 
manifestations of hepatitis C virus are underestimated but can be improved with therapy. Hepatol 
Commun 2017; 1: 439-452 [PMID: 29404471 DOI: 10.1002/hep4.1049]
3     
Sbarigia U, Kariburyo F, Sah J, Colasurdo J, Xie L, Katz EG, Sylvester S. Evaluating the Effect of 
Standard of Care Treatment on Burden of Chronic Hepatitis B: A Retrospective Analysis of the 
United States Veterans Population. Adv Ther 2020; 37: 1156-1172 [PMID: 32009232 DOI: 
10.1007/s12325-020-01240-1]
4     
Lee HW, Yip TC, Tse YK, Wong GL, Kim BK, Kim SU, Park JY, Kim DY, Chan HL, Ahn SH, 
Wong VW. Hepatic Decompensation in Cirrhotic Patients Receiving Antiviral Therapy for Chronic 
Hepatitis B. Clin Gastroenterol Hepatol 2020 [PMID: 32889148 DOI: 10.1016/j.cgh.2020.08.064]
5     
Papatheodoridis GV, Manolakopoulos S, Touloumi G, Vourli G, Raptopoulou-Gigi M, Vafiadis-
Zoumbouli I, Vasiliadis T, Mimidis K, Gogos C, Ketikoglou I, Manesis EK;  HEPNET. Greece 
Cohort Study Group. Virological suppression does not prevent the development of hepatocellular 
carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) 
starting with lamivudine monotherapy: results of the nationwide HEPNET. Greece cohort study. Gut 
2011; 60: 1109-1116 [PMID: 21270118 DOI: 10.1136/gut.2010.221846]
6     
Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging 
prevention and control measures. J Viral Hepat 2004; 11: 97-107 [PMID: 14996343 DOI: 
10.1046/j.1365-2893.2003.00487.x]
7     
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J 
Clin 2011; 61: 69-90 [PMID: 21296855 DOI: 10.3322/caac.20107]
8     
Matthews GR.   B Positive – All you wanted to know about hepatitis B: a guide for primary care 
providers. ASHM 2018. Available from: https://www.hepatitisb.org.au/
9     
Public Health England.   Acute hepatitis B (England): annual report for 2017 Health Protection 
Report: Volume 12 Number 31. Available from: https://allcatsrgrey.org.uk/wp/wpfb-
file/hpr3118_hepb-pdf/
10     
Public Health England.   Hepatitis B in the West Midlands: 2017 data. Available from: 
https://www.gov.uk/government/publications/hepatitis-b-virus-hbv-regional-reports
11     
Hepatitis Australia.   Hepatitis Statistics. 2020. Available from: 
https://www.hepatitisaustralia.com/hepatitis-
statistics?gclid=EAIaIQobChMIqpq9oM7w8QIVEpNmAh1DWgSwEAAYASAAEgIAFvD_BwE
12     
Wu CY, Lin JT, Ho HJ, Su CW, Lee TY, Wang SY, Wu C, Wu JC. Association of nucleos(t)ide 
analogue therapy with reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B: a 
nationwide cohort study. Gastroenterology 2014; 147: 143-151.e5 [PMID: 24704525 DOI: 
10.1053/j.gastro.2014.03.048]
13     
European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the 
management of hepatitis B virus infection. J Hepatol 2017; 67: 370-398 [PMID: 28427875 DOI: 
10.1016/j.jhep.2017.03.021]
14     
Luvisa BK, Hassanein TI. Hepatitis B Virus Infection and Liver Decompensation. Clin Liver Dis 
2016; 20: 681-692 [PMID: 27742007 DOI: 10.1016/j.cld.2016.07.002]
15     
Hui AY, Chan HL, Leung NW, Hung LC, Chan FK, Sung JJ. Survival and prognostic indicators in 
patients with hepatitis B virus-related cirrhosis after onset of hepatic decompensation. J Clin 
Gastroenterol 2002; 34: 569-572 [PMID: 11960072 DOI: 10.1097/00004836-200205000-00018]
16     
Das K, Das K, Datta S, Pal S, Hembram JR, Dhali GK, Santra A, Chowdhury A. Course of disease 
and survival after onset of decompensation in hepatitis B virus-related cirrhosis. Liver Int 2010; 30: 
1033-1042 [PMID: 20492502 DOI: 10.1111/j.1478-3231.2010.02255.x]
17     
Garg H, Sarin SK, Kumar M, Garg V, Sharma BC, Kumar A. Tenofovir improves the outcome in 
patients with spontaneous reactivation of hepatitis B presenting as acute-on-chronic liver failure. 
Hepatology 2011; 53: 774-780 [PMID: 21294143 DOI: 10.1002/hep.24109]
18     
Lin B, Pan CQ, Xie D, Xie J, Xie S, Zhang X, Wu B, Lin C, Gao Z. Entecavir improves the outcome 
of acute-on-chronic liver failure due to the acute exacerbation of chronic hepatitis B. Hepatol Int 
2013; 7: 460-467 [PMID: 26201778 DOI: 10.1007/s12072-012-9415-y]
19     
Kim CH, Um SH, Seo YS, Jung JY, Kim JD, Yim HJ, Keum B, Kim YS, Jeen YT, Lee HS, Chun 
HJ, Kim CD, Ryu HS. Prognosis of hepatitis B-related liver cirrhosis in the era of oral nucleos(t)ide 
analog antiviral agents. J Gastroenterol Hepatol 2012; 27: 1589-1595 [PMID: 22554121 DOI: 
10.1111/j.1440-1746.2012.07167.x]
20     
Shim JH, Lee HC, Kim KM, Lim YS, Chung YH, Lee YS, Suh DJ. Efficacy of entecavir in 
treatment-naïve patients with hepatitis B virus-related decompensated cirrhosis. J Hepatol 2010; 52: 
176-182 [PMID: 20006394 DOI: 10.1016/j.jhep.2009.11.007]
21     
Liaw YF, Raptopoulou-Gigi M, Cheinquer H, Sarin SK, Tanwandee T, Leung N, Peng CY, Myers 
RP, Brown RS Jr, Jeffers L, Tsai N, Bialkowska J, Tang S, Beebe S, Cooney E. Efficacy and safety of 
entecavir vs adefovir in chronic hepatitis B patients with hepatic decompensation: a randomized, 
open-label study. Hepatology 2011; 54: 91-100 [PMID: 21503940 DOI: 10.1002/hep.24361]
22     
Liaw YF, Sheen IS, Lee CM, Akarca US, Papatheodoridis GV, Suet-Hing Wong F, Chang TT, 
Horban A, Wang C, Kwan P, Buti M, Prieto M, Berg T, Kitrinos K, Peschell K, Mondou E, Frederick 
D, Rousseau F, Schiff ER. Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in 
patients with decompensated chronic hepatitis B liver disease. Hepatology 2011; 53: 62-72 [PMID: 
23     
Khoo T et al. Modern antiviral therapy and liver disease
WJG https://www.wjgnet.com 4842 August 7, 2021 Volume 27 Issue 29
21254162 DOI: 10.1002/hep.23952]
Peng CY, Chien RN, Liaw YF. Hepatitis B virus-related decompensated liver cirrhosis: benefits of 
antiviral therapy. J Hepatol 2012; 57: 442-450 [PMID: 22504333 DOI: 10.1016/j.jhep.2012.02.033]
24     
Cholongitas E, Papatheodoridis GV, Goulis J, Vlachogiannakos J, Karatapanis S, Ketikoglou J, 
Vasiliadis T, Kontos G, Karlaftis A, Akriviadis E. The impact of newer nucleos(t)ide analogues on 
patients with hepatitis B decompensated cirrhosis. Ann Gastroenterol 2015; 28: 109-117 [PMID: 
25608681]
25     
Jang JW, Choi JY, Kim YS, Woo HY, Choi SK, Lee CH, Kim TY, Sohn JH, Tak WY, Han KH. 
Long-term effect of antiviral therapy on disease course after decompensation in patients with hepatitis 
B virus-related cirrhosis. Hepatology 2015; 61: 1809-1820 [PMID: 25627342 DOI: 
10.1002/hep.27723]
26     
Tong MJ, Hsien C, Song JJ, Kao JH, Sun HE, Hsu L, Han SH, Durazo FA, Saab S, Blatt LM. Factors 
associated with progression to hepatocellular carcinoma and to death from liver complications in 
patients with HBsAg-positive cirrhosis. Dig Dis Sci 2009; 54: 1337-1346 [PMID: 19242792 DOI: 
10.1007/s10620-009-0747-y]
27     
Ma H, Guo F, Wei L, Sun Y, Wang H. [The prospective study of the clinical features and outcome of 
HBeAg-negative and HBeAg-positive cirrhosis in patients with chronic type B hepatitis]. Zhonghua 
Yi Xue Za Zhi 2007; 87: 1832-1835 [PMID: 17922993]
28     
Hosaka T, Suzuki F, Kobayashi M, Seko Y, Kawamura Y, Sezaki H, Akuta N, Suzuki Y, Saitoh S, 
Arase Y, Ikeda K, Kumada H. Long-term entecavir treatment reduces hepatocellular carcinoma 
incidence in patients with hepatitis B virus infection. Hepatology 2013; 58: 98-107 [PMID: 23213040 
DOI: 10.1002/hep.26180]
29     
Papatheodoridis GV, Chan HL, Hansen BE, Janssen HL, Lampertico P. Risk of hepatocellular 
carcinoma in chronic hepatitis B: assessment and modification with current antiviral therapy. J 
Hepatol 2015; 62: 956-967 [PMID: 25595883 DOI: 10.1016/j.jhep.2015.01.002]
30     
Lin D, Yang HI, Nguyen N, Hoang J, Kim Y, Vu V, Le A, Chaung K, Nguyen V, Trinh H, Li J, 
Zhang J, Hsing A, Chen CJ, Nguyen MH. Reduction of chronic hepatitis B-related hepatocellular 
carcinoma with anti-viral therapy, including low risk patients. Aliment Pharmacol Ther 2016; 44: 
846-855 [PMID: 27549411 DOI: 10.1111/apt.13774]
31     
Okada M, Enomoto M, Kawada N, Nguyen MH. Effects of antiviral therapy in patients with chronic 
hepatitis B and cirrhosis. Expert Rev Gastroenterol Hepatol 2017; 11: 1095-1104 [PMID: 28752768 
DOI: 10.1080/17474124.2017.1361822]
32     
Papatheodoridis GV, Idilman R, Dalekos GN, Buti M, Chi H, van Boemmel F, Calleja JL, Sypsa V, 
Goulis J, Manolakopoulos S, Loglio A, Siakavellas S, Keskın O, Gatselis N, Hansen BE, Lehretz M, 
de la Revilla J, Savvidou S, Kourikou A, Vlachogiannakos I, Galanis K, Yurdaydin C, Berg T, 
Colombo M, Esteban R, Janssen HLA, Lampertico P. The risk of hepatocellular carcinoma decreases 
after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B. Hepatology 
2017; 66: 1444-1453 [PMID: 28622419 DOI: 10.1002/hep.29320]
33     
Choi J, Han S, Kim N, Lim YS. Increasing burden of liver cancer despite extensive use of antiviral 
agents in a hepatitis B virus-endemic population. Hepatology 2017; 66: 1454-1463 [PMID: 28628942 
DOI: 10.1002/hep.29321]
34     
But DY, Lai CL, Yuen MF. Natural history of hepatitis-related hepatocellular carcinoma. World J 
Gastroenterol 2008; 14: 1652-1656 [PMID: 18350595 DOI: 10.3748/wjg.14.1652]
35     
Arzumanyan A, Reis HM, Feitelson MA. Pathogenic mechanisms in HBV- and HCV-associated 
hepatocellular carcinoma. Nat Rev Cancer 2013; 13: 123-135 [PMID: 23344543 DOI: 
10.1038/nrc3449]
36     
Köhn-Gaone J, Gogoi-Tiwari J, Ramm GA, Olynyk JK, Tirnitz-Parker JE. The role of liver 
progenitor cells during liver regeneration, fibrogenesis, and carcinogenesis. Am J Physiol Gastrointest 
Liver Physiol 2016; 310: G143-G154 [PMID: 26608186 DOI: 10.1152/ajpgi.00215.2015]
37     
Kew MC. Hepatitis B virus x protein in the pathogenesis of hepatitis B virus-induced hepatocellular 
carcinoma. J Gastroenterol Hepatol 2011; 26 Suppl 1: 144-152 [PMID: 21199526 DOI: 
10.1111/j.1440-1746.2010.06546.x]
38     
Kim GA, Lee HC, Kim MJ, Ha Y, Park EJ, An J, Lee D, Shim JH, Kim KM, Lim YS. Incidence of 
hepatocellular carcinoma after HBsAg seroclearance in chronic hepatitis B patients: a need for 
surveillance. J Hepatol 2015; 62: 1092-1099 [PMID: 25445399 DOI: 10.1016/j.jhep.2014.11.031]
39     
Papatheodoridis GV, Manolakopoulos S, Touloumi G, Nikolopoulou G, Raptopoulou-Gigi M, 
Gogos C, Vafiadis-Zouboulis I, Karamanolis D, Chouta A, Ilias A, Drakoulis C, Mimidis K, 
Ketikoglou I, Manesis E, Mela M, Hatzis G, Dalekos GN;  HepNet. Greece Study Group. 
Hepatocellular carcinoma risk in HBeAg-negative chronic hepatitis B patients with or without 
cirrhosis treated with entecavir: HepNet.Greece cohort. J Viral Hepat 2015; 22: 120-127 [PMID: 
25040685 DOI: 10.1111/jvh.12283]
40     
Simonetti J, Bulkow L, McMahon BJ, Homan C, Snowball M, Negus S, Williams J, Livingston SE. 
Clearance of hepatitis B surface antigen and risk of hepatocellular carcinoma in a cohort chronically 
infected with hepatitis B virus. Hepatology 2010; 51: 1531-1537 [PMID: 20087968 DOI: 
10.1002/hep.23464]
41     
Liu J, Yang HI, Lee MH, Lu SN, Jen CL, Batrla-Utermann R, Wang LY, You SL, Hsiao CK, Chen 
PJ, Chen CJ;  R. E.V.E.A.L.-HBV Study Group. Spontaneous seroclearance of hepatitis B 
seromarkers and subsequent risk of hepatocellular carcinoma. Gut 2014; 63: 1648-1657 [PMID: 
24225939 DOI: 10.1136/gutjnl-2013-305785]
42     
Khoo T et al. Modern antiviral therapy and liver disease
WJG https://www.wjgnet.com 4843 August 7, 2021 Volume 27 Issue 29
Kumada T, Toyoda H, Tada T, Kiriyama S, Tanikawa M, Hisanaga Y, Kanamori A, Niinomi T, 
Yasuda S, Andou Y, Yamamoto K, Tanaka J. Effect of nucleos(t)ide analogue therapy on 
hepatocarcinogenesis in chronic hepatitis B patients: a propensity score analysis. J Hepatol 2013; 58: 
427-433 [PMID: 23123221 DOI: 10.1016/j.jhep.2012.10.025]
43     
Wong GL, Chan HL, Mak CW, Lee SK, Ip ZM, Lam AT, Iu HW, Leung JM, Lai JW, Lo AO, Chan 
HY, Wong VW. Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients 
with liver cirrhosis. Hepatology 2013; 58: 1537-1547 [PMID: 23389810 DOI: 10.1002/hep.26301]
44     
Chuma M, Hige S, Kamiyama T, Meguro T, Nagasaka A, Nakanishi K, Yamamoto Y, Nakanishi M, 
Kohara T, Sho T, Yamamoto K, Horimoto H, Kobayashi T, Yokoo H, Matsushita M, Todo S, Asaka 
M. The influence of hepatitis B DNA level and antiviral therapy on recurrence after initial curative 
treatment in patients with hepatocellular carcinoma. J Gastroenterol 2009; 44: 991-999 [PMID: 
19554391 DOI: 10.1007/s00535-009-0093-z]
45     
Lim YS, Han S, Heo NY, Shim JH, Lee HC, Suh DJ. Mortality, liver transplantation, and 
hepatocellular carcinoma among patients with chronic hepatitis B treated with entecavir vs 
lamivudine. Gastroenterology 2014; 147: 152-161 [PMID: 24583062 DOI: 
10.1053/j.gastro.2014.02.033]
46     
Ayoub WS, Martin P, Bhamidimarri KR. Hepatitis B Virus Infection and Organ Transplantation. 
Gastroenterol Hepatol (N Y) 2018; 14: 33-40 [PMID: 29491759]
47     
Samuel D, Muller R, Alexander G, Fassati L, Ducot B, Benhamou JP, Bismuth H. Liver 
transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 1993; 329: 
1842-1847 [PMID: 8247035 DOI: 10.1056/NEJM199312163292503]
48     
Matsui T, Kang JH, Nojima M, Tomonari A, Aoki H, Yamazaki H, Yane K, Tsuji K, Andoh S, Sakai 
H, Maemori M, Maguchi H, Tanaka Y. Reactivation of hepatitis B virus in patients with undetectable 
HBsAg undergoing chemotherapy for malignant lymphoma or multiple myeloma. J Med Virol 2013; 
85: 1900-1906 [PMID: 23926082 DOI: 10.1002/jmv.23694]
49     
Cholongitas E, Papatheodoridis GV. High genetic barrier nucleos(t)ide analogue(s) for prophylaxis 
from hepatitis B virus recurrence after liver transplantation: a systematic review. Am J Transplant 
2013; 13: 353-362 [PMID: 23137006 DOI: 10.1111/j.1600-6143.2012.04315.x]
50     
Han SH. Extrahepatic manifestations of chronic hepatitis B. Clin Liver Dis 2004; 8: 403-418 [PMID: 
15481347 DOI: 10.1016/j.cld.2004.02.003]
51     
Cacoub P, Saadoun D, Bourlière M, Khiri H, Martineau A, Benhamou Y, Varastet M, Pol S, Thibault 
V, Rotily M, Halfon P. Hepatitis B virus genotypes and extrahepatic manifestations. J Hepatol 2005; 
43: 764-770 [PMID: 16087273 DOI: 10.1016/j.jhep.2005.05.029]
52     
Mallet V, Schwarzinger M, Vallet-Pichard A, Fontaine H, Corouge M, Sogni P, Pol S. Effect of 
nucleoside and nucleotide analogues on renal function in patients with chronic hepatitis B 
virus monoinfection. Clin Gastroenterol Hepatol 2015; 13: 1181-8.e1 [PMID: 25460550 DOI: 
10.1016/j.cgh.2014.11.021]
53     
Fu B, Ji Y, Hu S, Ren T, Bhuva MS, Li G, Yang H. Efficacy and safety of anti-viral therapy for 
Hepatitis B virus-associated glomerulonephritis: A meta-analysis. PLoS One 2020; 15: e0227532 
[PMID: 31940324 DOI: 10.1371/journal.pone.0227532]
54     
Guillevin L, Mahr A, Callard P, Godmer P, Pagnoux C, Leray E, Cohen P;  French Vasculitis Study 
Group. Hepatitis B virus-associated polyarteritis nodosa: clinical characteristics, outcome, and impact 
of treatment in 115 patients. Medicine (Baltimore) 2005; 84: 313-322 [PMID: 16148731 DOI: 
10.1097/01.md.0000180792.80212.5e]
55     
Hunder GG, Arend WP, Bloch DA, Calabrese LH, Fauci AS, Fries JF, Leavitt RY, Lie JT, Lightfoot 
RW Jr, Masi AT. The American College of Rheumatology 1990 criteria for the classification of 
vasculitis. Introduction. Arthritis Rheum 1990; 33: 1065-1067 [PMID: 2390119 DOI: 
10.1002/art.1780330802]
56     
de Menthon M, Mahr A. Treating polyarteritis nodosa: current state of the art. Clin Exp Rheumatol 
2011; 29: S110-S116 [PMID: 21586205]
57     
Mazzaro C, Dal Maso L, Visentini M, Gitto S, Andreone P, Toffolutti F, Gattei V. Hepatitis B virus-
related cryogobulinemic vasculitis. The role of antiviral nucleot(s)ide analogues: a review. J Intern 
Med 2019; 286: 290-298 [PMID: 31124596 DOI: 10.1111/joim.12913]
58     
Public Health England.   Hepatitis C in the UK 2020. 2020 Available from: https://assets.publishing.
service.gov.uk/government/uploads/system/uploads/attachment_data/file/943154/HCV_in_the_UK_2
020.pdf
59     
McDonald SA, Innes HA, Aspinall EJ, Hayes PC, Alavi M, Valerio H, Goldberg DJ, Hutchinson SJ. 
Inpatient hospital burden of hepatitis C-diagnosed patients with decompensated cirrhosis. Liver Int 
2018; 38: 1402-1410 [PMID: 29288595 DOI: 10.1111/liv.13681]
60     
Yin S, Barker L, Teshale EH, Jiles RB. Rising Trends in Emergency Department Visits Associated 
With Hepatitis C Virus Infection in the United States, 2006-2014. Public Health Rep 2019; 134: 685-
694 [PMID: 31577517 DOI: 10.1177/0033354919878437]
61     
Cheung MCM, Walker AJ, Hudson BE, Verma S, McLauchlan J, Mutimer DJ, Brown A, Gelson 
WTH, MacDonald DC, Agarwal K, Foster GR, Irving WL;  HCV Research UK. Outcomes after 
successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated 
cirrhosis. J Hepatol 2016; 65: 741-747 [PMID: 27388925 DOI: 10.1016/j.jhep.2016.06.019]
62     
Nahon P, Bourcier V, Layese R, Audureau E, Cagnot C, Marcellin P, Guyader D, Fontaine H, Larrey 
D, De Lédinghen V, Ouzan D, Zoulim F, Roulot D, Tran A, Bronowicki JP, Zarski JP, Leroy V, 
Riachi G, Calès P, Péron JM, Alric L, Bourlière M, Mathurin P, Dharancy S, Blanc JF, Abergel A, 
63     
Khoo T et al. Modern antiviral therapy and liver disease
WJG https://www.wjgnet.com 4844 August 7, 2021 Volume 27 Issue 29
Serfaty L, Mallat A, Grangé JD, Attali P, Bacq Y, Wartelle C, Dao T, Benhamou Y, Pilette C, Silvain 
C, Christidis C, Capron D, Bernard-Chabert B, Zucman D, Di Martino V, Thibaut V, Salmon D, Ziol 
M, Sutton A, Pol S, Roudot-Thoraval F;  ANRS CO12 CirVir Group. Eradication of Hepatitis C Virus 
Infection in Patients With Cirrhosis Reduces Risk of Liver and Non-Liver Complications. 
Gastroenterology 2017; 152: 142-156.e2 [PMID: 27641509 DOI: 10.1053/j.gastro.2016.09.009]
Ioannou GN, Feld JJ. What Are the Benefits of a Sustained Virologic Response to Direct-Acting 
Antiviral Therapy for Hepatitis C Virus Infection? Gastroenterology 2019; 156: 446-460.e2 [PMID: 
30367836 DOI: 10.1053/j.gastro.2018.10.033]
64     
Mandorfer M, Kozbial K, Schwabl P, Freissmuth C, Schwarzer R, Stern R, Chromy D, Stättermayer 
AF, Reiberger T, Beinhardt S, Sieghart W, Trauner M, Hofer H, Ferlitsch A, Ferenci P, Peck-
Radosavljevic M. Sustained virologic response to interferon-free therapies ameliorates HCV-induced 
portal hypertension. J Hepatol 2016; 65: 692-699 [PMID: 27242316 DOI: 
10.1016/j.jhep.2016.05.027]
65     
Afendy A, Kallman JB, Stepanova M, Younoszai Z, Aquino RD, Bianchi G, Marchesini G, Younossi 
ZM. Predictors of health-related quality of life in patients with chronic liver disease. Aliment 
Pharmacol Ther 2009; 30: 469-476 [PMID: 19508612 DOI: 10.1111/j.1365-2036.2009.04061.x]
66     
Kallman J, O'Neil MM, Larive B, Boparai N, Calabrese L, Younossi ZM. Fatigue and health-related 
quality of life (HRQL) in chronic hepatitis C virus infection. Dig Dis Sci 2007; 52: 2531-2539 
[PMID: 17406828 DOI: 10.1007/s10620-006-9708-x]
67     
Cacoub P, Bourliere M, Asselah T, De Ledinghen V, Mathurin P, Hézode C, Henry L, Stepanova M, 
Younossi ZM. French Patients with Hepatitis C Treated with Direct-Acting Antiviral Combinations: 
The Effect on Patient-Reported Outcomes. Value Health 2018; 21: 1218-1225 [PMID: 30314623 
DOI: 10.1016/j.jval.2018.01.006]
68     
Younossi Z, Park H, Henry L, Adeyemi A, Stepanova M. Extrahepatic Manifestations of Hepatitis C: 
A Meta-analysis of Prevalence, Quality of Life, and Economic Burden. Gastroenterology 2016; 150: 
1599-1608 [PMID: 26924097 DOI: 10.1053/j.gastro.2016.02.039]
69     
Kanwal F, Kramer J, Asch SM, Chayanupatkul M, Cao Y, El-Serag HB. Risk of Hepatocellular 
Cancer in HCV Patients Treated With Direct-Acting Antiviral Agents. Gastroenterology 2017; 153: 
996-1005.e1 [PMID: 28642197 DOI: 10.1053/j.gastro.2017.06.012]
70     
Ioannou GN, Green PK, Berry K. HCV eradication induced by direct-acting antiviral agents reduces 
the risk of hepatocellular carcinoma. J Hepatol 2017 [PMID: 28887168 DOI: 
10.1016/j.jhep.2017.08.030]
71     
Singer AW, Reddy KR, Telep LE, Osinusi AO, Brainard DM, Buti M, Chokkalingam AP. Direct-
acting antiviral treatment for hepatitis C virus infection and risk of incident liver cancer: a 
retrospective cohort study. Aliment Pharmacol Ther 2018; 47: 1278-1287 [PMID: 29516535 DOI: 
10.1111/apt.14593]
72     
Nahon P, Layese R, Bourcier V, Cagnot C, Marcellin P, Guyader D, Pol S, Larrey D, De Lédinghen 
V, Ouzan D, Zoulim F, Roulot D, Tran A, Bronowicki JP, Zarski JP, Riachi G, Calès P, Péron JM, 
Alric L, Bourlière M, Mathurin P, Blanc JF, Abergel A, Serfaty L, Mallat A, Grangé JD, Attali P, 
Bacq Y, Wartelle C, Dao T, Thabut D, Pilette C, Silvain C, Christidis C, Nguyen-Khac E, Bernard-
Chabert B, Zucman D, Di Martino V, Sutton A, Roudot-Thoraval F, Audureau E;  ANRS CO12 
CirVir Group. Incidence of Hepatocellular Carcinoma After Direct Antiviral Therapy for HCV in 
Patients With Cirrhosis Included in Surveillance Programs. Gastroenterology 2018; 155: 1436-
1450.e6 [PMID: 30031138 DOI: 10.1053/j.gastro.2018.07.015]
73     
Mettke F, Schlevogt B, Deterding K, Wranke A, Smith A, Port K, Manns MP, Vogel A, Cornberg M, 
Wedemeyer H. Interferon-free therapy of chronic hepatitis C with direct-acting antivirals does not 
change the short-term risk for de novo hepatocellular carcinoma in patients with liver cirrhosis. 
Aliment Pharmacol Ther 2018; 47: 516-525 [PMID: 29205405 DOI: 10.1111/apt.14427]
74     
Schwabl P, Mandorfer M, Steiner S, Scheiner B, Chromy D, Herac M, Bucsics T, Hayden H, 
Grabmeier-Pfistershammer K, Ferlitsch A, Oberhuber G, Trauner M, Peck-Radosavljevic M, 
Reiberger T. Interferon-free regimens improve portal hypertension and histological 
necroinflammation in HIV/HCV patients with advanced liver disease. Aliment Pharmacol Ther 2017; 
45: 139-149 [PMID: 27910154 DOI: 10.1111/apt.13844]
75     
Fernandes FF, Piedade J, Guimaraes L, Nunes EP, Chaves U, Goldenzon RV, Cardoso SW, Duarte 
J, Grinsztejn B, Veloso VG, Pereira G, Perazzo H. Effectiveness of direct-acting agents for hepatitis C 
and liver stiffness changing after sustained virological response. J Gastroenterol Hepatol 2019; 34: 
2187-2195 [PMID: 31062880 DOI: 10.1111/jgh.14707]
76     
Tada T, Kumada T, Toyoda H, Sone Y, Takeshima K, Ogawa S, Goto T, Wakahata A, Nakashima 
M, Nakamuta M, Tanaka J. Viral eradication reduces both liver stiffness and steatosis in patients with 
chronic hepatitis C virus infection who received direct-acting anti-viral therapy. Aliment Pharmacol 
Ther 2018; 47: 1012-1022 [PMID: 29424449 DOI: 10.1111/apt.14554]
77     
Yamada R, Hiramatsu N, Oze T, Urabe A, Tahata Y, Morishita N, Kodama T, Hikita H, Sakamori R, 
Yakushijin T, Yamada A, Hagiwara H, Mita E, Oshita M, Itoh T, Fukui H, Inui Y, Hijioka T, Inada 
M, Katayama K, Tamura S, Inoue A, Imai Y, Tatsumi T, Hamasaki T, Hayashi N, Takehara T. 
Incidence and risk factors of hepatocellular carcinoma change over time in patients with hepatitis C 
virus infection who achieved sustained virologic response. Hepatol Res 2019; 49: 570-578 [PMID: 
30623521 DOI: 10.1111/hepr.13310]
78     
Dultz G, Zeuzem S. Hepatitis C Virus: A European Perspective. Gastroenterol Clin North Am 2015; 
44: 807-824 [PMID: 26600221 DOI: 10.1016/j.gtc.2015.07.008]
79     
Khoo T et al. Modern antiviral therapy and liver disease
WJG https://www.wjgnet.com 4845 August 7, 2021 Volume 27 Issue 29
Muzica CM, Stanciu C, Huiban L, Singeap AM, Sfarti C, Zenovia S, Cojocariu C, Trifan A. 
Hepatocellular carcinoma after direct-acting antiviral hepatitis C virus therapy: A debate near the end. 
World J Gastroenterol 2020; 26: 6770-6781 [PMID: 33268960 DOI: 10.3748/wjg.v26.i43.6770]
80     
Vaziri A, Gimson A, Agarwal K, Aldersley M, Bathgate A, MacDonald D, McPherson S, Mutimer D, 
Gelson W. Liver transplant listing for hepatitis C-associated cirrhosis and hepatocellular carcinoma 
has fallen in the United Kingdom since the introduction of direct-acting antiviral therapy. J Viral 
Hepat 2019; 26: 231-235 [PMID: 30339294 DOI: 10.1111/jvh.13022]
81     
Belli LS, Berenguer M, Cortesi PA, Strazzabosco M, Rockenschaub SR, Martini S, Morelli C, Donato 
F, Volpes R, Pageaux GP, Coilly A, Fagiuoli S, Amaddeo G, Perricone G, Vinaixa C, Berlakovich G, 
Facchetti R, Polak W, Muiesan P, Duvoux C;  European Liver and Intestine Association (ELITA). 
Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: A European 
study. J Hepatol 2016; 65: 524-531 [PMID: 27212241 DOI: 10.1016/j.jhep.2016.05.010]
82     
Perricone G, Duvoux C, Berenguer M, Cortesi PA, Vinaixa C, Facchetti R, Mazzarelli C, 
Rockenschaub SR, Martini S, Morelli C, Monico S, Volpes R, Pageaux GP, Fagiuoli S, Belli LS; 
European Liver and Intestine Transplant Association (ELITA). Delisting HCV-infected liver 
transplant candidates who improved after viral eradication: Outcome 2 years after delisting. Liver Int 
2018; 38: 2170-2177 [PMID: 29750389 DOI: 10.1111/liv.13878]
83     
Petta S, Maida M, Macaluso FS, Barbara M, Licata A, Craxì A, Cammà C. Hepatitis C Virus 
Infection Is Associated With Increased Cardiovascular Mortality: A Meta-Analysis of Observational 
Studies. Gastroenterology 2016; 150: 145-155.e4; quiz e15 [PMID: 26386298 DOI: 
10.1053/j.gastro.2015.09.007]
84     
Nevola R, Rinaldi L, Zeni L, Sasso FC, Pafundi PC, Guerrera B, Marrone A, Giordano M, Adinolfi 
LE. Metabolic and renal changes in patients with chronic hepatitis C infection after hepatitis C virus 
clearance by direct-acting antivirals. JGH Open 2020; 4: 713-721 [PMID: 32782961 DOI: 
10.1002/jgh3.12324]
85     
Ciancio A, Bosio R, Bo S, Pellegrini M, Sacco M, Vogliotti E, Fassio G, Bianco Mauthe Degerfeld 
AGF, Gallo M, Giordanino C, Terzi di Bergamo L, Ribaldone D, Bugianesi E, Smedile A, Rizzetto 
M, Saracco GM. Significant improvement of glycemic control in diabetic patients with HCV infection 
responding to direct-acting antiviral agents. J Med Virol 2018; 90: 320-327 [PMID: 28960353 DOI: 
10.1002/jmv.24954]
86     
Dong TS, Aby ES, Benhammou JN, Kawamoto J, Han SH, May FP, Pisegna JR. Metabolic syndrome 
does not affect sustained virologic response of direct-acting antivirals while hepatitis C clearance 
improves hemoglobin A1c. World J Hepatol 2018; 10: 612-621 [PMID: 30310539 DOI: 
10.4254/wjh.v10.i9.612]
87     
Weidner P, Boettche D, Zimmerer T, Burgermeister E, Teufel A, Ebert MPA, Antoni C. Impact of 
direct acting antiviral (DAA) treatment on glucose metabolism and reduction of pre-diabetes in 
patients with chronic hepatitis C. J Gastrointestin Liver Dis 2018; 27: 281-289 [PMID: 30240472 
DOI: 10.15403/jgld.2014.1121.273.daa]
88     
Abdel Alem S, Elsharkawy A, Fouad R, Adel E, Abdellatif Z, Musa S, Nagy A, Hussein MS, Yosry 
A, Esmat G. Improvement of glycemic state among responders to Sofosbuvir-based treatment 
regimens: Single center experience. J Med Virol 2017; 89: 2181-2187 [PMID: 28688190 DOI: 
10.1002/jmv.24897]
89     
Elhelbawy M, Abdel-Razek W, Alsebaey A, Hashim M, Elshenawy H, Waked I. Insulin resistance 
does not impair response of chronic hepatitis C virus to direct-acting antivirals, and improves with the 
treatment. Eur J Gastroenterol Hepatol 2019; 31: 16-23 [PMID: 30024489 DOI: 
10.1097/MEG.0000000000001215]
90     
El Sagheer G, Soliman E, Ahmad A, Hamdy L. Study of changes in lipid profile and insulin 
resistance in Egyptian patients with chronic hepatitis C genotype 4 in the era of DAAs. Libyan J Med 
2018; 13: 1435124 [PMID: 29451090 DOI: 10.1080/19932820.2018.1435124]
91     
Carvalho JR, Velosa J, Serejo F. Lipids, glucose and iron metabolic alterations in chronic hepatitis C 
after viral eradication - comparison of the new direct-acting antiviral agents with the old regimens. 
Scand J Gastroenterol 2018; 53: 857-863 [PMID: 29779403 DOI: 10.1080/00365521.2018.1473486]
92     
Inoue T, Goto T, Iio E, Matsunami K, Fujiwara K, Shinkai N, Matsuura K, Matsui T, Nojiri S, 
Tanaka Y. Changes in serum lipid profiles caused by three regimens of interferon-free direct-acting 
antivirals for patients infected with hepatitis C virus. Hepatol Res 2018; 48: E203-E212 [PMID: 
28834042 DOI: 10.1111/hepr.12970]
93     
Meissner EG, Lee YJ, Osinusi A, Sims Z, Qin J, Sturdevant D, McHutchison J, Subramanian M, 
Sampson M, Naggie S, Patel K, Remaley AT, Masur H, Kottilil S. Effect of sofosbuvir and ribavirin 
treatment on peripheral and hepatic lipid metabolism in chronic hepatitis C virus, genotype 1-infected 
patients. Hepatology 2015; 61: 790-801 [PMID: 25203718 DOI: 10.1002/hep.27424]
94     
Hashimoto S, Yatsuhashi H, Abiru S, Yamasaki K, Komori A, Nagaoka S, Saeki A, Uchida S, Bekki 
S, Kugiyama Y, Nagata K, Nakamura M, Migita K, Nakao K. Rapid Increase in Serum Low-Density 
Lipoprotein Cholesterol Concentration during Hepatitis C Interferon-Free Treatment. PLoS One 2016; 
11: e0163644 [PMID: 27680885 DOI: 10.1371/journal.pone.0163644]
95     
Abdel Moez AT, El Hawary YA, Al Balakosy AM. Can successful treatment by direct-acting 
antivirals improve depression in chronic HCV patients? Eur J Gastroenterol Hepatol 2021; 33: 727-
730 [PMID: 32558698 DOI: 10.1097/MEG.0000000000001790]
96     
Published by Baishideng Publishing Group Inc 
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA 
Telephone: +1-925-3991568 
E-mail: bpgoffice@wjgnet.com 
Help Desk: https://www.f6publishing.com/helpdesk 
https://www.wjgnet.com
© 2021 Baishideng Publishing Group Inc. All rights reserved.
